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 Abstract 
 Background: Post-stroke hyperglycaemia (PSH) is associated with higher mortality and depen-
dence, but further data on predictors of PSH and its evolution over time are required. We exam-
ined the prevalence, predictors, and prognosis of acute PSH using data from well-characterised 
clinical trials in the VISTA database.  Methods: Data were extracted for individual participants 
enrolled  ! 24 h after stroke with  6 1 blood glucose readings documented. PSH was defined as 
glucose  1 7.0 mmol/l. Outcome measures were: (1) prevalence of PSH; (2) predictors of PSH by 
binary logistic regression; (3) mortality, and (4) favourable functional outcome [modified Rankin 
Scale (mRS) score  ! 2] at day 90.  Results: For 2,649 subjects treated at a median 5.5 h after ad-
mission, PSH was present in 1,126 (42.6%, 95% CI 40.7–44.5) on admission and within the first
48 h in 1,421 (53.7%, 95% CI 51.8–55.6). PSH developed between 24 and 48 h in 19.4% (95% CI 
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17.5–21.4) of initially normoglycaemic subjects. Admission and 48-hour PSH were predicted pre-
dominantly by a history of diabetes (for admission PSH: OR 7.40, 95% CI 5.60–9.79) and less 
clearly by stroke severity. Favourable outcome (mRS  ! 2) at day 90 was less likely with PSH with-
in the first 48 h, advanced age, and higher NIHSS score, and more likely with recombinant tissue 
plasminogen activator treatment.  Conclusions: Over 40% of ischaemic stroke patients are hy-
perglycaemic on admission, and 20% of those who are initially normoglycaemic develop hyper-
glycaemia within 48 h. Diabetes is the strongest predictor of acute hyperglycaemia. Hypergly-
caemia within the first 48 h is independently associated with higher mortality and poorer 
functional outcome, with an absolute increase of 12.9%.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Post-stroke hyperglycaemia (PSH) is recognised as a predictor of poor outcome, and in-
tervention to lower glucose is widely recommended by clinical guidelines. However, there is 
a paucity of evidence on key issues concerning hyperglycaemia, and recent results of clinical 
trials raise concerns about the safety of insulin therapy.
 In a meta-analysis of observational studies, hyperglycaemia was associated with increased 
relative risks of both death and of death or dependence in non-diabetic patients after stroke 
 [1] , but the studies included in this meta-analysis were predominantly retrospective and het-
erogeneous, with no consistent definitions of the glucose level that defined hyperglycaemia or 
timing of blood sampling. Individual studies reached divergent conclusions on outcome  [2] . 
More recent analyses from more homogeneous clinical populations (either in randomised, 
controlled trials of intravenous thrombolysis or of populations receiving intravenous throm-
bolysis as routine therapy) confirm an independent adverse prognostic association of early 
hyperglycaemia, potentially related to an increased risk of symptomatic intracranial haemor-
rhage  [3, 4] , attenuation of the benefit of alteplase on infarct growth  [5] or recanalisation  [4, 6] .
 The estimated prevalence of hyperglycaemia has varied widely among studies (8–63%  [1, 
7, 8] ), probably as a result of several factors, including varying thresholds for defining hyper-
glycaemia in different studies, different sampling methods, and different times of blood sam-
pling. The temporal profile of blood or tissue glucose after stroke is complex  [4, 9] . Solitary 
glucose measurements underestimate the incidence of hyperglycaemia, and admission glu-
cose alone does not predict early infarct expansion on brain imaging, or poor 3-month out-
come, whereas more frequent, or continuous, measurements of glucose do  [9] , and glucose 
levels over the first 48 h after stroke appear to be the most significant predictor of outcome  [6] .
 However, only a minority of patients remain normoglycaemic throughout the first 24 h 
after stroke (15% in the ECASS-2 cohort), and only a minority of those with sustained hy-
perglycaemia exhibit hyperglycaemia on admission  [4] . Identification of and appropriate se-
lection of patients for glucose-lowering interventions are therefore unclear. Several possible 
predictors of hyperglycaemia have been proposed by different studies. These often include 
stroke severity  [10–12] (some authors postulating that the association with poor outcome is 
an artefact, dependent primarily on stroke severity), but also prior dysglycaemia  [13, 14] . An 
association of hyperglycaemia with catecholamine concentrations has been lacking  [15] , and 
suggestions of a specific neuroanatomical trigger have not been supported, at least for hyper-
glycaemia present within the first 3–6 h after stroke onset  [16–20] .
 In addition, insulin treatment in patients with modest hyperglycaemia (median 7.6 
mmol/l) starting on average 13 h after stroke in GIST-UK was not beneficial  [21] , and other 
trials in stroke  [22] and medical intensive care patients  [23] highlight potential dangers of 
aggressive glucose lowering.
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 More robust additional data on PSH are therefore required, particularly regarding pre-
dictors of hyperglycaemia and whether factors such as increasing  [24] or sustained  [6] eleva-
tion of blood glucose are more important markers of risk than a solitary measurement. We 
sought to establish the prevalence of hyperglycaemia in acute stroke trial populations and to 
explore the predictors and prognostic value of hyperglycaemia at different times after stroke 
onset by interrogating individual patient data from VISTA  [25] .
 Methods 
 Individual patient data were obtained from VISTA  [25] , which includes individual pa-
tient data from placebo groups (and some active treatment groups) of stroke trials. Data are 
anonymised with respect to individual trial identifiers. Trials which met the following crite-
ria were sought: (1) trials of acute intervention initiated within 24 h of stroke onset, and (2) 
protocol-defined recording of blood glucose at least on admission.
 Anonymised data included age, sex, medical history, blood glucose concentration on 
admission (and at any other available time point during the initial 72 h of a trial), National 
Institutes of Health Stroke Scale (NIHSS) score on admission, day-90 modified Rankin Scale 
(mRS) score and mortality. Onset to randomisation or treatment time was assumed to be a 
reasonable surrogate for the time of initial blood glucose concentration (designated admis-
sion blood glucose) since hypo- or hyperglycaemia was generally an exclusion criterion for 
trials, and blood results before randomisation therefore would have to be available.
 Hyperglycaemia was defined as blood glucose  1 7 mmol/l (126 mg/dl). The influence of 
hyperglycaemia on outcome was evaluated both for admission hyperglycaemia and for hy-
perglycaemia documented at any time within 48 h of trial inclusion. In the population for 
whom  6 2 blood glucose measurements were available, increase in blood glucose from ad-
mission was also explored as a predictive factor. Additionally, different thresholds of blood 
glucose to define hyperglycaemia were tested in exploratory analyses.
 Descriptive data were prepared for all subjects for whom admission blood glucose con-
centration was available. Predictors of hyperglycaemia on admission or at any time within 
the first 48 h of trial inclusion were identified by a forward stepwise binary logistic regres-
sion model. Predictors of death at day 90 and favourable outcome at day 90 (defined as mRS 
0–1) were looked for using the same method. This search was conducted for the entire 
population with  6 1 blood glucose readings available and was repeated for the subgroup 
for whom  1 1 blood glucose reading was available within the first 72 h after randomisation 
in order to explore the effect of increase in blood glucose on outcome. Baseline demograph-
ic and prognostic indices were compared by t tests for normally distributed data, Mann-
Whitney U tests for non-normally distributed data, and   2 tests for discrete categorical 
variables.
 Results 
 Data were available for 2,898 subjects in trials fulfilling the criteria. Valid admission 
blood glucose was available for 2,649 subjects, who comprised the study population. Trial 
time windows ranged from 4.5 to 24 h. Median time from disease onset to treatment was
5.5 h. No information was available on treatment with insulin or oral hypoglycaemic agents 
during the trials, or on the policies of participating units regarding hyperglycaemia manage-
ment. Haemoglobin A 1c was not documented in any trial.
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 Baseline characteristics of the population as a whole, and divided according to presence 
or absence of hyperglycaemia  1 7 mmol/l on admission, are presented in  table 1 . Data on 
prior diagnosis of diabetes mellitus were available for 2,645 subjects.
 Prevalence 
 Admission hyperglycaemia was present in 1,126 of 2,645 subjects (42.6%, 95% CI 40.7–
44.5) and hyperglycaemia at some point within the first 48 h in 1,421 of 2,645 subjects (53.7%, 
95% CI 51.8–55.6). Hyperglycaemia was present on admission in 36.3% of non-diabetics and 
80.9% of diabetics, and was documented within 48 h of admission in 48.1% of non-diabetics 
and 88.1% of diabetics.
 Hyperglycaemia was documented between 24 and 48 h after study enrolment in 296 of 
1,522 subjects (19.4%, 95% CI 17.5–21.4) who were normoglycaemic on admission. An in-
crease in blood glucose between admission and 48 h was documented in 908 of 1,913 subjects 
(47.5%, 95% CI 45.2–49.7) for whom data were available, 647 of 1,068 subjects who were ini-
tially normoglycaemic (60.6%) and 261 of 845 subjects (30.9%) who were initially hypergly-
caemic (p  ! 0.001). An increase in blood glucose from admission was documented in a high-
er proportion of patients with less severe strokes (53.9% in the lowest vs. 44.7% in the highest 
quartile of NIHSS scores; p = 0.0205,   2 test for trend).
Table 1.  Baseline characteristics of the study population
Normoglycaemia
(≤7.0 mmol/l)
Hyperglycaemia
(>7.0 mmol/l)
All p
Subjects, n 1,522 1,127 2,649
Age, years 66.9813.0 69.4810.5 68.0812.1 <0.001
Sex
Male 868 (57.0%) 602 (53.4%) 1,470 (55.5%) 0.069
Female 654 (43.0%) 525 (46.6%) 1,179 (44.5%)
Onset-to-treatment time, h 5.6 (4.1–9.8) 5.3 (4.0–7.8) 5.5 (4.0–8.8) 0.007
Onset-to-treatment interval
0–3 h 142 (9.4%) 109 (9.8%) 251 (9.6%) 0.004
3–6 h 907 (60.2%) 732 (65.8%) 1,639 (62.6%)
6–12 h 294 (19.5%) 189 (17.0%) 483 (18.4%)
12–24 h 164 (10.9%) 83 (7.5%) 247 (9.4%)
rtPA treatment 648/1,522 (42.6%) 454/1,127 (40.3%) 1,102/2,649 (41.6%) 0.248
Admission NIHSS score 13 (8–18) 15 (10–20) 14 (9–19) <0.001
Glucose, mmol/l
Admission 5.8280.77 10.1483.48 <0.001
Highest documented level (24–48 h) 6.5982.01 9.1383.69 <0.001
Change from admission +0.7882.06 –0.9283.50 <0.001
Medical history
Transient ischaemic attack 131/1,315 (10.0%) 99/1,037 (9.5%) 230/2,352 (9.8%) 0.780
Previous stroke 122/698 (17.5%) 100/524 (19.1%) 222/1,222 (18.2%) 0.500
Myocardial infarction 98/1,315 (7.5%) 102/1,037 (9.8%) 200/2,352 (8.5%) 0.044
Hypertension 670/1,315 (51.0%) 616/1,037 (59.4%) 1,286/2,352 (54.7%) <0.001
Atrial fibrillation 158/936 (16.9%) 127/740 (17.2%) 285/1,676 (17.0%) 0.896
Smokers
Never 887 (58.4%) 711 (63.1%) 1,598 (60.4%) 0.005
Current 305 (20.1%) 172 (15.3%) 477 (18.0%)
Ex- or passive 327 (21.5%) 243 (21.6%) 570 (21.6%)
Diabetes 71/1,519 (4.7%) 300/1,126 (26.6%) 371/2,645 (14.0%) <0.001
V alues are means 8 SD or medians with interquartile ranges in parentheses, unless otherwise indicated. 
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 Predictors 
 Hyperglycaemia on admission was more likely with a history of diabetes and a higher 
 NIHSS score, and was less likely when blood was sampled later after stroke onset ( table 2 a). 
Diabetes was associated with an odds ratio (OR) of 7.40 (95% CI 5.60–9.79) for admission hy-
perglycaemia. The OR of hyperglycaemia in the highest quartile of NIHSS scores (scores  6 19) 
was 1.6 compared to the lowest quartile (scores 0–8). The same factors were associated with 
hyperglycaemia within the first 48 h, with the addition of a history of hypertension and ad-
vanced age ( table 2 b). Again, diabetes was the strongest predictor (OR 7.91, 95% CI 5.65–11.08).
 Prognosis 
 mRS score at day 90 was documented in 2,392 subjects. Predictors of favourable outcome 
(mRS 0 or 1) at day 90 are listed in  table 3 a. Hyperglycaemia within the first 48 h, advanced 
age, and NIHSS score were associated with a reduced likelihood of favourable outcome, while 
recombinant tissue plasminogen activator (rtPA) treatment was associated with an increased 
likelihood of favourable outcome.
 Predictors of death at day 90 are listed in  table 3 b. Hyperglycaemia within the first 48 h, 
increasing age and stroke severity were associated with a greater likelihood of death, while 
rtPA treatment was associated with a reduced likelihood of death. Other factors (including 
admission glucose and admission hyperglycaemia) were not significant. Day-90 mRS catego-
ries are shown for normoglycaemic subjects and for subjects with hyperglycaemia within
48 h ( fig. 1 ). The absolute difference in favourable outcome (mRS 0–1) was 12.9% (95% CI 
9.2–16.7). Outcome was poorer with hyperglycaemia with or without rtPA treatment ( fig. 2 a) 
and at all quartiles of the admission NIHSS score ( fig. 2 b).
 For the subgroup of 1,624 subjects in whom additional blood glucose recordings were 
available after admission, 761 exhibited an increase of at least 0.01 mol/l, while in 863 blood 
glucose decreased or remained unchanged after admission. Since numbers were evenly dis-
tributed, this may represent regression to the mean. Diabetes was associated with a twofold 
increase in risk of increasing blood glucose, while higher admission glucose or the presence 
of admission hyperglycaemia were associated with a reduced risk. In this subgroup, prognos-
Table 2. P redictors of hyperglycaemia >7 mmol/l
a On admission
Factor OR 95% CI p
Time window 6–12 vs. 0–3 h 0.49 0.34–0.71 0.0001
Time window 12–24 vs. 0–3 h 0.50 0.33–0.75 0.0009
Admission NIHSS score (per 4 points) 1.14 1.08–1.21 <0.0001
Diabetes mellitus 7.40 5.60–9.79 <0.0001
Non-predictive variables were age, sex, rtPA treatment, history of transient ischemic attack, myocar-
dial infarction, hypertension or smoking status.
b Within the first 48 h
Age (per 10 years) 1.12 1.03–1.21 0.006
Time window 6–12 vs. 0–3 h 0.48 0.33–0.69 0.0001
Time window 12–24 vs. 0–3 h 0.37 0.24–0.56 <0.0001
Admission NIHSS score (per 4 points) 1.15 1.09–1.21 <0.0001
Hypertension 1.27 1.06–1.52 0.0102
Diabetes mellitus 7.91 5.65–11.08 <0.0001
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 Fig. 1. Day-90 outcome on mRS 
by presence or absence of hyper-
glycaemia  1 7 mmol/l within the 
first 48 h. 0–6 = Categories on 
the mRS. 
 Fig. 2. Day-90 outcome on mRS 
by presence or absence of hyper-
glycaemia  1 7 mmol/l within the 
first 48 h and intravenous rtPA 
treatment ( a ).  b Quartiles of ad-
mission NIHSS score. H = Hy-
perglycaemia; N = normoglycae-
mia. 
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tic markers were evaluated with a further logistic regression model: data for 1,360 subjects 
with complete information on all factors could be included in the model, and a favourable 
outcome was significantly associated with rtPA treatment and less likely with increasing age, 
NIHSS score, presence of hyperglycaemia within 48 h, and also with increased blood glucose 
levels from admission ( table 3 c). Likelihood of death at 3 months was significantly associ-
ated with advanced age, rtPA treatment, time window, NIHSS score, smoking status, hyper-
glycaemia within 48 h and also increase in blood glucose.
 Exploratory analyses repeated the logistic regression models with different thresholds of 
hyperglycaemia (10, 15, and  1 15 mmol/l). No alternative definition was independently sig-
nificant when hyperglycaemia  1 7 mmol/l within the first 48 h was included in the model.
 Discussion 
 Observational studies consistently identify PSH to be associated with increased mortal-
ity and reduced likelihood of a good recovery, with a meta-analysis of older observational 
studies reporting a relative risk of death by 30 days of 3 and a relative risk of death or depen-
dence of 1.41 in non-diabetics with PSH  [1] and more recent observational studies in less 
heterogeneous clinical populations confirming this association  [3–6] . Treatment of PSH re-
mains an area of clinical uncertainty  [26–28] , and insulin treatment was ineffective in the 
only large randomised controlled trial on stroke, although the trial was underpowered and 
had a number of other issues that raise questions about its generalisability  [21] . Other recent 
Table 3.  Predictors of a favourable outcome and mortality at day 90 in all subjects, and predictors of a fa-
vourable outcome in patients with ≥1 blood glucose measurements
a Favourable outcome (mRS 0–1) in all subjects
Factor OR 95% CI p
Age, per 10 years 0.86 0.78–0.95 0.002
rtPA treatment 1.35 1.09–1.69 0.007
Admission NIHSS score (per 4 points) 0.44 0.40–0.48 <0.001
Ex- or passive smoker vs. never smoker 1.46 1.11–1.91 0.006
Hyperglycaemia within 48 h 0.70 0.56–0.87 0.002
b Mortality at day 90 in all subjects
Age, per 10 years 1.83 1.55–2.17 <0.001
Male sex 1.36 0.99–1.85 0.052
Current smoker vs. never or ex-smoker 1.68 1.11–2.56 0.015
rtPA treatment 0.49 0.35–0.69 <0.001
Admission NIHSS score (per 4 points) 1.67 1.52–1.83 <0.001
Hyperglycaemia within 48 h 1.66 1.23–2.25 0.001
c Favourable outcome (mRS 0–1) in patients with ≥1 blood glucose measurements (n = 1,360)
Age, per 10 years 0.82 0.73–0.91 <0.001
rtPA treatment 1.43 1.11–1.84 0.006
Admission NIHSS score (per 4 points) 0.48 0.43–0.54 <0.001
Hyperglycaemia within 48 h 0.58 0.45–0.75 <0.001
Increase from initial blood glucose 0.73 0.57–0.95 0.017
D
ow
nl
oa
de
d 
by
: 
G
la
sg
ow
 U
ni
v.
Li
b.
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
20
9.
6.
42
 - 
12
/2
4/
20
13
 1
2:
49
:0
9 
PM
24
Cerebrovasc Dis Extra 2011;1:17–27
 DOI: 10.1159/000324319 
E X T R A
 Muir et al.: Prevalence, Predictors and Prognosis of PSH in Acute Stroke Trials 
www.karger.com/cee
 © 2011 S. Karger AG, Basel
 Published online: March 2, 2011 
trials highlight potential for insulin to worsen outcome  [29] . If current guidelines to inter-
vene with aggressive glucose lowering were universally implemented, previous data suggest 
that the proportion of stroke patients requiring insulin infusions would range from 13% if 
based on acute admission values only (which are of doubtful prognostic value except where 
thrombolysis is given) to 86% within the first 24 h  [4] . Single values have less prognostic 
value than sustained hyperglycaemia, and hyperglycaemia at any time within 48 h following 
admission may be more relevant than single recordings  [6] . This insight has potentially ma-
jor implications for stroke management, given the major staffing requirements for insulin 
infusion management and high incidence of hypoglycaemia in stroke unit settings  [30] . In 
this context, further information on the predictors and natural history of PSH is necessary.
 The VISTA database offers a large cohort of participants in acute stroke trials with rig-
orous source data verification, a median time from stroke onset to admission of  ! 6 h, and a 
high treatment rate with intravenous thrombolysis. The population is wider than that en-
countered in thrombolysis trials or registers, although a high proportion in this dataset re-
ceived such treatment. We confirmed a high prevalence of hyperglycaemia in acute stroke 
patients, and we also found that diabetes was a far stronger predictor than stroke severity. 
We moreover confirmed that the presence of elevated blood glucose during the first 48 h af-
ter admission for stroke was more strongly associated with a poorer chance of favourable 
outcome than was a single acute high glucose measurement.
 The prevalence of hyperglycaemia (43% on admission, rising to 54% documented with-
in 48 h of stroke) almost certainly underestimates the true prevalence since trial protocols 
generally exclude patients with very high glucose, and most available trial datasets docu-
mented only 1 blood glucose concentration. More frequent blood glucose measurements in-
dicate a profile of increasing blood glucose over the first 24 h after stroke  [9] .
 The odds of hyperglycaemia either on admission or within 48 h were increased sevenfold 
in those with a diagnosis of diabetes. Diabetes also predicted the likelihood of an increase in 
blood glucose after admission. In contrast, the contribution of stroke severity was much less. 
This finding suggests that pre-existing abnormalities of blood glucose levels are the most 
important predictors of acute hyperglycaemia, which is consistent with acute PSH being 
probably more suited as a marker of underlying insulin resistance  [13] than the concept of 
‘stress hyperglycaemia’ related to acute physiological stress  [14, 31] . Follow-up of stroke sur-
vivors identifies a very high prevalence of insulin resistance phenotypes, present in up to 77% 
 [13, 32] . The association of an increase in blood glucose with less severe stroke is an intrigu-
ing finding that suggests that introduction of feeding in this group may add further complex-
ity to the prediction of hyperglycaemia.
 The detrimental effect of hyperglycaemia within the first 48 h on 3-month outcome was 
confirmed, being associated with both higher mortality and a reduced likelihood of good 
recovery. Furthermore, in the subset of patients in whom  1 1 blood glucose measurement was 
documented, increase in blood glucose was also an independent predictor of poor outcome.
 The VISTA dataset offers well-validated multisite data and therefore allows clinical 
questions to be addressed in a large database of acute stroke patients, but it has several limi-
tations. The trials included in VISTA were not designed to study blood glucose, and thus they 
did not document certain important measures: for example, absence of haemoglobin A 1c 
concentration makes it impossible to distinguish undiagnosed diabetes from ‘stress’ hyper-
glycaemia. Blood glucose was documented after admission in only around two thirds of pa-
tients, and the timing of repeat sampling ranged from 24 to 72 h. We do not know whether 
blood sampling coincided with trial randomisation or which method was used for blood glu-
cose measurement, although it is reasonable to assume that sampling was performed at acute 
presentation and that whole blood laboratory glucose measurement was the standard meth-
od. Important interventions that may impact on glucose measurement were not reported, 
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most prominently feeding status, intravenous fluid regimes, and hypoglycaemic medication. 
While most trial protocols prohibit experimental interventions other than the intervention 
being tested, it is possible that local investigators may have intervened to control blood glu-
cose according to local interpretation of guidelines, which is known to vary widely  [33] . In-
evitably, amalgamation of different trial datasets imposes limitations due to differences in 
recording of medical history variables, and incomplete data restricted the terms that could 
be used in the regression models. Although our decision to define hyperglycaemia based on 
a threshold of 7 mmol/l is arbitrary, it is one of several thresholds employed in the previous 
literature, and no alternative index of hyperglycaemia was superior in regression models 
when this threshold was included. Consistent with the prospective observational data from 
the GLIAS study  [6] , we also found that hyperglycaemia documented at any time within
48 h was a better predictor of outcome than admission values. If the detrimental effect of 
hyperglycaemia is not confined to the very early time periods when hyperglycaemia might 
be expected to influence infarct growth or haemorrhagic transformation risk, alternative 
mechanisms for adverse outcomes should be identified. This observation also implies that 
short-term insulin treatment regimes (e.g. 24 h in GIST-UK  [21] ) may be insufficient and is 
consistent with a retrospective analysis of medical intensive care patients, in whom 72-hour 
intensive insulin therapy was necessary for benefit  [34] .
 Faced with limited evidence, guidelines offer different recommendations regarding 
management, and the stroke physicians’ behaviour reflects this uncertainty  [28, 33] . Recent 
experience from acute myocardial infarction and intensive care unit trials that failed to rep-
licate initially positive reports of intervention and identified potential hazards due to hypo-
glycaemia should give pause for thought  [35–39] . Despite many potential mechanisms where-
by hyperglycaemia might be harmful in the evolution of ischaemic brain damage  [40, 41] , it 
remains possible that it is simply a marker for poor prognosis due to unrecognised insulin 
resistance. With the exception of increased symptomatic intracerebral haemorrhage risk in 
thrombolysis patients, and a possible attenuation of the beneficial effect of intravenous rtPA 
on infarct growth, it remains unclear whether the association of hyperglycaemia with poor 
outcome represents an effect on acute infarct evolution or on later adverse events, since most 
studies report only 3-month outcomes.
 The results of our analysis emphasise the necessity of documenting blood glucose in all 
acute stroke trials. The detrimental effect of hyperglycaemia within the first 48 h, an absolute 
reduction in favourable outcome of almost 13%, is greater than the treatment effect of intra-
venous rtPA, and hyperglycaemia should be included as a stratifying variable in all acute 
stroke trials.
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